You are using an older browser version. Please use a supported version for the best MSN experience.

VASCULAR BIOGENICS LTD

NASDAQ: VBLT
1.26
-0.02
-1.56%

Sector

Healthcare

Industry

Biotechnology & Medical Research

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Key People

Bennett Shapiro

Chairman of the Board, Independent Director

Dror Harats

Chief Executive Officer, Director

Amos Ron

Chief Financial Officer & Company Secretary

Eyal Breitbart

Vice President - Research & Operations

Erez Feige

Vice President - Business Operations

  • Vascular Biogenics Ltd

  • 8 HaSatat St.

  • MODIIN, 7178106

  • IL.Map

  • Phone: +972 8 9935000

  • Fax: +972 8 9935001

  • vblrx.com

Incorporated

2000

Employees

37

Insider Trades
  • Recent
  • All
Data not available
Data not available
AdChoices
AdChoices
AdChoices
image beaconimage beaconimage beacon